<MedlineCitation Status="Completed">
<MedlineID>10011927</MedlineID>
<PMID>84706</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2001</Year>
<Month>03</Month>
<Day>23</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0008-543X</ISSN>
<JournalIssue>
<Volume>43</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.</ArticleTitle>
<Pagination>
<MedlinePgn>417-25</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>As a part of an ongoing prospective controlled trial, the Southwest Oncology Group compared the results of treatment of advanced non-Hodgkin's lymphoma with two CHOP regimens (cyclophosphamide, adriamycin, vincristine and prednisone with either low-dose bleomycin or BCG by scarification) to a COP regimen (cyclophosphamide, vincristine and prednisone) with low-dose bleomycin (COP-Bleo). The study design emphasized histopathology review and systematic restaging to define complete remission (CR). Confirmed rates of CR for 443 evaluable patients were 59% for 286 patients receiving the CHOP regimens and 59% for 157 patients receiving COP-Bleo. Rates of CR were higher for patients with nodular lymphoma (69%) compared to those with diffuse lymphoma (54%) (p = 0.005). For patients with nodular lymphoma there was no difference in CR rates according to treatment. For patients with diffuse lymphomas the CR rate was higher with the CHOP programs (58%) than with COP-Bleo (44%) (p = 0.10). Overall duration of CR and survival was significantly longer for patients with nodular lymphoma compared to diffuse lymphoma (p less than 0.01). At this time, remission duration and survival were similar regardless of induction regimen used in patients with nodular lymphoma. However, in patients with diffuse lymphoma, the duration of CR and overall survival were improved by treatment with the CHOP regimens compared to COP-Bleo (p = 0.02). Thus, in this controlled study we have demonstrated that initial combination chemotherapy employing the CHOP regimen was a superior remission induction therapy for patients with diffuse lymphoma.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Jones</LastName>
<ForeName>S E</ForeName>
<Initials>SE</Initials>
</Author>
<Author>
<LastName>Grozea</LastName>
<ForeName>P N</ForeName>
<Initials>PN</Initials>
</Author>
<Author>
<LastName>Metz</LastName>
<ForeName>E N</ForeName>
<Initials>EN</Initials>
</Author>
<Author>
<LastName>Haut</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Stephens</LastName>
<ForeName>R L</ForeName>
<Initials>RL</Initials>
</Author>
<Author>
<LastName>Morrison</LastName>
<ForeName>F S</ForeName>
<Initials>FS</Initials>
</Author>
<Author>
<LastName>Butler</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Author>
<Author>
<LastName>Byrne</LastName>
<ForeName>G E</ForeName>
<Initials>GE</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author>
<LastName>Moon</LastName>
<ForeName>T E</ForeName>
<Initials>TE</Initials>
</Author>
<Author>
<LastName>Fisher</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author>
<LastName>Haskins</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
</Author>
<Author>
<LastName>Coltman</LastName>
<ForeName>C A</ForeName>
<Initials>CA</Initials>
<Suffix>Jr</Suffix>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Controlled Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>BCG Vaccine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>11056-06-7</RegistryNumber>
<NameOfSubstance>Bleomycin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>23214-92-8</RegistryNumber>
<NameOfSubstance>Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-18-0</RegistryNumber>
<NameOfSubstance>Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>53-03-2</RegistryNumber>
<NameOfSubstance>Prednisone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>57-22-7</RegistryNumber>
<NameOfSubstance>Vincristine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &#38; dosage</QualifierName>
<QualifierName>adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>BCG Vaccine</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Bleomycin</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Clinical Trials</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Comparative Study</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cyclophosphamide</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Doxorubicin</DescriptorName>
<QualifierName MajorTopicYN="Y">administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Prednisone</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Remission, Spontaneous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Vincristine</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
